XETRA - Delayed Quote EUR

Merck KGaA (MRK.DE)

151.30 +1.00 (+0.67%)

At close: October 30 at 5:35:28 PM GMT+1

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and Roche

GlobeNewswire 15h ago

ALNY

ROP.SW

TMO
Global Pooled CRISPR Screening Market Report 2026 | Capitalize on 16.1% CAGR as Thermo Fisher, Merck, Danaher and Agilent Accelerate AI-Driven Multi-Omics Workflows

GlobeNewswire 1d ago

TMO

DHR

A
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

Zacks 1d ago

RXRX

SNY

ROP.SW
MilliporeSigma Announces the Opening of €300 Million Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea

GlobeNewswire 1d ago

MRK.DE
+0.67%
Lisa Morales Joins Vinson & Elkins as NY-Based Corporate Partner

CorpGov.com 2d ago

JPM

ETOR

MRK.DE
+0.67%
ProtaGene Appoints Former Merck KGaA CDMO Leader Matthias Bucerius as Chief Executive Officer

GlobeNewswire 3d ago

MRK.DE
+0.67%
Global Human Osteoblasts Market Report 2026 | Capitalize on $53.09 Billion Revenue Share by 2030 as Merck KGaA, Thermo Fisher Scientific, Lonza and STEMCELL Lead the Industry

GlobeNewswire 9d ago

MRK.DE
+0.67%
TMO
Merck KGaA (XTRA:MRK) Stock Seems Hard To Call After Its 30% Run

Simply Wall St. 10d ago

MRK.DE
+0.67%
Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics

Pharmaceutical Technology 10d ago

MRK.DE
+0.67%
MRK
Is Merck KGaA (XTRA:MRK) Undervalued On Silence Therapeutics Deal News?

Simply Wall St. 11d ago

MRK.DE
+0.67%
Merck KGaA (XTRA:MRK) Makes A Rare Disease Bet With A Phase 3 Ready siRNA Deal

Simply Wall St. 11d ago

MRK.DE
+0.67%
Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%

Insider Monkey 11d ago

MRK.DE
+0.67%
MRK

SLN

Performance Overview

Return	MRK.DE	DAX P (^GDAXI)
YTD	+25.88%	+5.42%
1-Year	+37.13%	+7.05%
3-Year	+15.71%	+75.44%

U.S. markets closed

Merck KGaA (MRK.DE)

Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and Roche

Global Pooled CRISPR Screening Market Report 2026 | Capitalize on 16.1% CAGR as Thermo Fisher, Merck, Danaher and Agilent Accelerate AI-Driven Multi-Omics Workflows

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

MilliporeSigma Announces the Opening of €300 Million Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea

Lisa Morales Joins Vinson & Elkins as NY-Based Corporate Partner

ProtaGene Appoints Former Merck KGaA CDMO Leader Matthias Bucerius as Chief Executive Officer

Global Human Osteoblasts Market Report 2026 | Capitalize on $53.09 Billion Revenue Share by 2030 as Merck KGaA, Thermo Fisher Scientific, Lonza and STEMCELL Lead the Industry

Merck KGaA (XTRA:MRK) Stock Seems Hard To Call After Its 30% Run

Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics

Is Merck KGaA (XTRA:MRK) Undervalued On Silence Therapeutics Deal News?

Merck KGaA (XTRA:MRK) Makes A Rare Disease Bet With A Phase 3 Ready siRNA Deal

Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%